Ryan Deschner
Stock Analyst at Raymond James
(4.81)
# 113
Out of 5,182 analysts
20
Total ratings
88.89%
Success rate
72.36%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ryan Deschner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLS Apellis Pharmaceuticals | Downgrades: Market Perform | n/a | $40.99 | - | 3 | Apr 1, 2026 | |
| PVLA Palvella Therapeutics | Upgrades: Strong Buy | $92 → $143 | $125.96 | +13.53% | 2 | Nov 19, 2025 | |
| TVRD Tvardi Therapeutics | Downgrades: Market Perform | n/a | $3.19 | - | 2 | Oct 14, 2025 | |
| LQDA Liquidia | Maintains: Strong Buy | $33 → $41 | $37.65 | +8.90% | 4 | Aug 13, 2025 | |
| TRVI Trevi Therapeutics | Maintains: Strong Buy | $29 → $27 | $13.84 | +95.09% | 3 | Aug 8, 2025 | |
| ARDX Ardelyx | Maintains: Outperform | $11 → $12 | $5.97 | +101.01% | 2 | Aug 5, 2025 | |
| VKTX Viking Therapeutics | Maintains: Strong Buy | $125 → $122 | $32.39 | +276.66% | 1 | Jul 24, 2025 | |
| SPRY ARS Pharmaceuticals | Maintains: Strong Buy | $26 → $28 | $7.94 | +252.64% | 3 | Jan 14, 2025 |
Apellis Pharmaceuticals
Apr 1, 2026
Downgrades: Market Perform
Price Target: n/a
Current: $40.99
Upside: -
Palvella Therapeutics
Nov 19, 2025
Upgrades: Strong Buy
Price Target: $92 → $143
Current: $125.96
Upside: +13.53%
Tvardi Therapeutics
Oct 14, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $3.19
Upside: -
Liquidia
Aug 13, 2025
Maintains: Strong Buy
Price Target: $33 → $41
Current: $37.65
Upside: +8.90%
Trevi Therapeutics
Aug 8, 2025
Maintains: Strong Buy
Price Target: $29 → $27
Current: $13.84
Upside: +95.09%
Ardelyx
Aug 5, 2025
Maintains: Outperform
Price Target: $11 → $12
Current: $5.97
Upside: +101.01%
Viking Therapeutics
Jul 24, 2025
Maintains: Strong Buy
Price Target: $125 → $122
Current: $32.39
Upside: +276.66%
ARS Pharmaceuticals
Jan 14, 2025
Maintains: Strong Buy
Price Target: $26 → $28
Current: $7.94
Upside: +252.64%